丙型肝炎病毒假病毒颗粒（HCVpp）抗体中和作用研究的标准化方法。
Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
作者信息
Bailey Justin R, Urbanowicz Richard A, Ball Jonathan K, Law Mansun, Foung Steven K H
机构信息
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
School of Life Sciences, The University of Nottingham, Nottingham, UK.
出版信息
Methods Mol Biol. 2019;1911:441-450. doi: 10.1007/978-1-4939-8976-8_30.
Abstract
Hepatitis C virus (HCV) pseudoparticles (HCVpp) are generated by cotransfection of HCV envelope (E1 and E2) genes along with a retroviral packaging/reporter construct into HEK293T cells. Enveloped particles bearing HCV E1E2 proteins on their surface are released through a retroviral budding process into the supernatant. Viral E1E2 glycoproteins facilitate a single round of receptor-mediated entry of HCVpp into hepatoma cells, which can be quantified by reporter gene expression. These HCVpp have been employed to study mechanisms of HCV entry into hepatoma cells, as well as HCV neutralization by immune sera or HCV-specific monoclonal antibodies.
摘要
丙型肝炎病毒（HCV）假病毒颗粒（HCVpp）是通过将HCV包膜（E1和E2）基因与逆转录病毒包装/报告构建体共转染到HEK293T细胞中产生的。表面带有HCV E1E2蛋白的包膜颗粒通过逆转录病毒出芽过程释放到上清液中。病毒E1E2糖蛋白促进HCVpp进行一轮受体介导的进入肝癌细胞的过程，这可以通过报告基因表达进行定量。这些HCVpp已被用于研究HCV进入肝癌细胞的机制，以及免疫血清或HCV特异性单克隆抗体对HCV的中和作用。
相似文献
1
Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
Methods Mol Biol. 2019;1911:441-450. doi: 10.1007/978-1-4939-8976-8_30.
2
A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
J Virol. 2015 Dec 23;90(7):3288-301. doi: 10.1128/JVI.02700-15.
3
Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells.
Hum Antibodies. 2013;22(3-4):55-65. doi: 10.3233/HAB-140271.
4
Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
J Gen Virol. 2016 Nov;97(11):2883-2893. doi: 10.1099/jgv.0.000608. Epub 2016 Sep 21.
5
Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp).
Methods Mol Biol. 2009;510:427-38. doi: 10.1007/978-1-59745-394-3_32.
6
Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
Mol Biol Rep. 2014 Jun;41(6):3945-50. doi: 10.1007/s11033-014-3262-y. Epub 2014 Feb 25.
7
Defining Breadth of Hepatitis C Virus Neutralization.
Front Immunol. 2018 Aug 2;9:1703. doi: 10.3389/fimmu.2018.01703. eCollection 2018.
8
[Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays].
Bing Du Xue Bao. 2008 Jul;24(4):287-94.
9
N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
Biochim Biophys Acta. 2016 Aug;1860(8):1764-75. doi: 10.1016/j.bbagen.2015.08.007. Epub 2015 Aug 14.
10
A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Antiviral Res. 2017 Dec;148:53-64. doi: 10.1016/j.antiviral.2017.10.015. Epub 2017 Oct 23.
引用本文的文献
1
Coordinated expansion of memory T follicular helper and B cells mediates spontaneous clearance of HCV reinfection.
Front Immunol. 2024 Jun 10;15:1403769. doi: 10.3389/fimmu.2024.1403769. eCollection 2024.
2
Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance.
Immunity. 2024 Apr 9;57(4):890-903.e6. doi: 10.1016/j.immuni.2024.03.001. Epub 2024 Mar 21.
3
Characterization of antibody-dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes.
J Med Virol. 2024 Jan;96(1):e29381. doi: 10.1002/jmv.29381.
4
Pseudotyped Virus for Flaviviridae.
Adv Exp Med Biol. 2023;1407:313-327. doi: 10.1007/978-981-99-0113-5_17.
5
[Development approaches for vaccines against hepatitis C virus infections].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Feb;65(2):183-191. doi: 10.1007/s00103-021-03477-9. Epub 2022 Jan 11.
6
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?
World J Hepatol. 2021 Oct 27;13(10):1234-1268. doi: 10.4254/wjh.v13.i10.1234.
7
An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.
Gastroenterology. 2022 Feb;162(2):562-574. doi: 10.1053/j.gastro.2021.10.005. Epub 2021 Oct 13.
8
Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins.
Immunity. 2021 Apr 13;54(4):781-796.e4. doi: 10.1016/j.immuni.2021.02.013. Epub 2021 Mar 5.
9
Early T follicular helper cell activity accelerates hepatitis C virus-specific B cell expansion.
J Clin Invest. 2021 Jan 19;131(2). doi: 10.1172/JCI140590.
10
Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.
J Gen Virol. 2021 Jan;102(1). doi: 10.1099/jgv.0.001512.
本文引用的文献
1
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance.
JCI Insight. 2017 May 4;2(9). doi: 10.1172/jci.insight.92872.
2
Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
J Gen Virol. 2016 Nov;97(11):2883-2893. doi: 10.1099/jgv.0.000608. Epub 2016 Sep 21.
3
Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.
J Gen Virol. 2016 Sep;97(9):2265-2279. doi: 10.1099/jgv.0.000537. Epub 2016 Jul 6.
4
Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
J Virol. 2016 Apr 14;90(9):4530-4543. doi: 10.1128/JVI.02669-15. Print 2016 May.
5
A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
J Virol. 2015 Dec 23;90(7):3288-301. doi: 10.1128/JVI.02700-15.
6
Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.
J Clin Invest. 2015 Jan;125(1):437-47. doi: 10.1172/JCI78794. Epub 2014 Dec 15.
7
Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses.
Hepatology. 2014 Jun;59(6):2140-51. doi: 10.1002/hep.27013. Epub 2014 Apr 29.
8
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.
PLoS Pathog. 2012;8(8):e1002895. doi: 10.1371/journal.ppat.1002895. Epub 2012 Aug 30.
9
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
PLoS Pathog. 2012;8(4):e1002653. doi: 10.1371/journal.ppat.1002653. Epub 2012 Apr 12.
10
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6205-10. doi: 10.1073/pnas.1114927109. Epub 2012 Apr 4.
Zotero 插件